Atara Biotherapeutics, Inc. (ATRA) Financials

ATRA Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 21.0 million 58.0 million
March 31, 2026 20.0 million 57.3 million
Dec. 31, 2025 20.2 million 58.7 million
Sept. 30, 2025 30.2 million 66.8 million

ATRA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -3.3 million 394000
March 31, 2026 -3.1 million 749000
Dec. 31, 2025 -5.7 million 1.5 million
Sept. 30, 2025 -9.8 million 1.2 million

ATRA Net Income

No data available :(

ATRA Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 9.9 million 8.8 million -
March 31, 2026 8.4 million 9.1 million 1.0 million
Dec. 31, 2025 8.5 million 32.7 million 9.3 million
Sept. 30, 2025 13.7 million 32.0 million 15.0 million

ATRA Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 14.6 million
March 31, 2026 14.1 million
Dec. 31, 2025 12.7 million
Sept. 30, 2025 13.6 million

ATRA Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 1.3 million 3.8 million -
March 31, 2026 - 164000 3.6 million -
Dec. 31, 2025 - -223000 4.3 million -
Sept. 30, 2025 - 2.9 million 4.0 million -

ATRA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 630000 191000
March 31, 2026 516000 124000
Dec. 31, 2025 1.6 million 104000
Sept. 30, 2025 3.5 million 115000

ATRA

Price: $8.09

52 week price:
3.92
19.15

Earnings Per Share: -1.26 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 783100

Ebitda: -31.4 million

Market Capitalization: 83.1 million

Links: